6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE

Identification

Name
6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
Accession Number
DB07606
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 465.717
Monoisotopic: 464.020973487
Chemical Formula
C20H15Cl3N4O3
InChI Key
OPRAIFVPXXVXDL-UHFFFAOYSA-N
InChI
InChI=1S/C20H15Cl3N4O3/c1-2-13-17-19(27(26-13)18-11(22)7-10(21)8-12(18)23)24-16(25-20(17)30)6-9-3-4-14(28)15(29)5-9/h3-5,7-8,28-29H,2,6H2,1H3,(H,24,25,30)
IUPAC Name
6-[(3,4-dihydroxyphenyl)methyl]-3-ethyl-1-(2,4,6-trichlorophenyl)-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one
SMILES
CCC1=NN(C2=C1C(=O)NC(CC1=CC(O)=C(O)C=C1)=N2)C1=C(Cl)C=C(Cl)C=C1Cl

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UCyclin-dependent kinase 2Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5327057
PubChem Substance
99444077
ChemSpider
20120282
BindingDB
6021
ChEMBL
CHEMBL425181
HET
D05
PDB Entries
2b54

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0173 mg/mLALOGPS
logP5.31ALOGPS
logP4.82ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)8.87ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area99.74 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity117.32 m3·mol-1ChemAxon
Polarizability44.12 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7089
Caco-2 permeable-0.6243
P-glycoprotein substrateSubstrate0.5973
P-glycoprotein inhibitor INon-inhibitor0.8393
P-glycoprotein inhibitor IINon-inhibitor0.7895
Renal organic cation transporterNon-inhibitor0.9007
CYP450 2C9 substrateNon-substrate0.709
CYP450 2D6 substrateNon-substrate0.8245
CYP450 3A4 substrateSubstrate0.6345
CYP450 1A2 substrateNon-inhibitor0.6779
CYP450 2C9 inhibitorInhibitor0.5738
CYP450 2D6 inhibitorNon-inhibitor0.8205
CYP450 2C19 inhibitorNon-inhibitor0.6236
CYP450 3A4 inhibitorNon-inhibitor0.7322
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8514
Ames testNon AMES toxic0.5877
CarcinogenicityNon-carcinogens0.7061
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4524 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9756
hERG inhibition (predictor II)Non-inhibitor0.7449
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Pyrazoles
Direct Parent
Phenylpyrazoles
Alternative Parents
Pyrazolo[3,4-d]pyrimidines / Catechols / Pyrimidones / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids / Chlorobenzenes / Aryl chlorides / Vinylogous amides / Heteroaromatic compounds / Lactams
show 7 more
Substituents
Phenylpyrazole / Pyrazolopyrimidine / Pyrazolo[3,4-d]pyrimidine / Catechol / Phenol / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Chlorobenzene / Pyrimidone / Halobenzene
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
trichlorobenzene, pyrazolopyrimidine (CHEBI:47364)

Targets

Details
1. Cyclin-dependent kinase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, N...
Gene Name
CDK2
Uniprot ID
P24941
Uniprot Name
Cyclin-dependent kinase 2
Molecular Weight
33929.215 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 15, 2010 15:24 / Updated on December 01, 2017 15:53